Literature DB >> 6186319

Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells.

M Beran, M Hansson, R Kiessling.   

Abstract

The effect of allogenic human natural killer (NK) cells on fresh leukemic cells from three patients was investigated. The low levels of leukemic target cell lysis in the conventional 51Cr-release assay contrasted with a pronounced inhibitory effect on the colony growth of the clonogeneic leukemic target cells (L-CFC). The ability of allogeneic lymphocytes to inhibit L-CFC increased if they were pretreated with interferon (IFN), which also increased their NK activity, monitored in parallel cytotoxicity assay, against K562. Furthermore, cell separation procedures, based on differences in density among nonadherent lymphocytes, revealed that only NK cell containing fractions were inhibitory. We have also compared the susceptibility to NK-mediated L-CFC inhibition of IFN pretreated leukemic target cells with that of nontreated target cells. As in the case of NK lysis in general, this pretreatment of target cells abolished the presumably NK-mediated L-CFC inhibition. In conclusion, these data provide the first indication that NK cells can inhibit the in vitro growth of fresh clonogenic leukemia cells from patients with nonlymphocytic leukemia. The identity of NK cells as effector is strongly suggested by Percoll separation and responsiveness to interferon; the final proof awaits more sophisticated purification of these cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6186319

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Ability of recombinant interferon gamma in vitro to restore the defective polymorphonuclear-cell- but not lymphocyte-mediated cytotoxic activities in patients with myelodysplastic syndromes.

Authors:  G De Sanctis; V Bottari; A Frezzolini; M Ficcardi; G De Rossi; M C Petti; F Mandelli; L Fontana
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study.

Authors:  S H Lim; A C Newland; S Kelsey; A Bell; E Offerman; C Rist; D Gozzard; D Bareford; M P Smith; A H Goldstone
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Normal natural killer cell activity in Hodgkin's disease patients in remission.

Authors:  D Douer; N Shaked; B Ramot
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

4.  The use of VEP13 monoclonal antibody for definition of natural killer cells: spontaneous killer cells directed against fresh human leukaemia cells carry the VEP13 antigen.

Authors:  H W Ziegler-Heitbrock; A Fütterer; H Rumpold; D Kraft; R Munker; G Riethmüller
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

5.  Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission.

Authors:  G Pizzolo; L Trentin; F Vinante; C Agostini; R Zambello; M Masciarelli; C Feruglio; F Dazzi; G Todeschini; M Chilosi
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

Review 6.  Natural immunity to tumours--theoretical predictions and biological observations.

Authors:  M Moore
Journal:  Br J Cancer       Date:  1985-08       Impact factor: 7.640

Review 7.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.